Clinical Trial Goal
To find out:
- The highest dose of TAB004 that's safe to give with or without toripalimab
- If TAB004 with or without toripalimab is safe and works well to treat lymphoma or solid tumors
You may be able to join this trial if you:
- Are 18 years or older
- Have lymphoma. Some examples include:
- Burkitt lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
- Marginal zone B-cell lymphoma
- Small lymphocytic lymphoma (SLL)
- Other non-Hodgkin lymphoma
- Waldenström's macroglobulinaemia
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
TAB004 is a monoclonal antibiody that targets BTLA.
Toripalimab is a monoclonal antibody and checkpoint inhibitor that targets PD-1 in certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Toripalimab is a monoclonal antibody and checkpoint inhibitor that targets PD-1 in certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- TAB004 – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
- Toripalimab – Given as an IV infusion. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 2 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has not yet approved TAB004 or toripalimab.
Locations
Sponsors
collaborator: Shanghai Junshi Bioscience Co., Ltd., collaborator: CTI Clinical Trial and Consulting Services, lead: TopAlliance Biosciences
